Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Catalyst PharmaceuticalsFRA:CN2 93 PB Ratio is 3.81 as of Jul. 22, 2026, which is 1% above its 10-year median of 3.79. GuruFocus rates FRA:CN2 with a GF Score™ of 93/100 and a GF Value™ of €20.73 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,229 Biotechnology companies, Catalyst Pharmaceuticals ranks worse than 61.68% on this metric.
Catalyst Pharmaceuticals Inc stock PB Ratio (=3.8) is close to 1-year high of 3.8.
The historical rank and industry rank for Catalyst Pharmaceuticals's PB Ratio or its related term are showing as below:
FRA:CN2'
s PB Ratio Range Over the Past 10 Years
Min: 1.97 Med: 3.79 Max: 12.17
Current: 3.8
During the past 13 years, Catalyst Pharmaceuticals's highest PB Ratio was 12.17. The lowest was 1.97. And the median was 3.79.
FRA:CN2's PB Ratio is ranked worse than 61.68% of 1229
companies
in the Biotechnology industry
Industry Median: 2.79
vs FRA:CN2: 3.80
During the past 12 months, Catalyst Pharmaceuticals's average Book Value Per Share Growth Rate was 27.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 39.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 38.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 33.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Catalyst Pharmaceuticals was 425.10% per year. The lowest was -41.30% per year. And the median was 25.60% per year.
Back to Basics: PB Ratio
Catalyst Pharmaceuticals (FRA:CN2) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Catalyst Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalyst Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Catalyst Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Catalyst Pharmaceuticals (FRA:CN2) has a PB Ratio of 3.81 as of Jul. 22, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Catalyst Pharmaceuticals and its competitors. This is near median its historical median of 3.79. Over the past decade, Catalyst Pharmaceuticals' PB Ratio has ranged from 1.97 to 12.17. According to the industry distribution chart, Catalyst Pharmaceuticals ranks #758 out of 1229 companies in the Biotechnology industry, placing it in the top 61.7%.
Is Catalyst Pharmaceuticals' PB Ratio too high?
Catalyst Pharmaceuticals' current PB Ratio of 3.81 is near median its 10-year median of 3.79. Over the past 10 years, this metric has ranged from a low of 1.97 to a high of 12.17. The Biotechnology industry median PB Ratio is 2.79. Catalyst Pharmaceuticals' value of 3.81 is 36.6% above this industry median. Based on the distribution chart, Catalyst Pharmaceuticals ranks #758 out of 1229 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Catalyst Pharmaceuticals has a GF Score™ of 93/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' PB Ratio compare to CRNX and NAMS?
According to the Biotechnology industry distribution chart, Catalyst Pharmaceuticals ranks #758 out of 1229 companies for PB Ratio. This places Catalyst Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.79. Catalyst Pharmaceuticals' value of 3.81 is 36.6% above this benchmark. Historically, Catalyst Pharmaceuticals' own PB Ratio has ranged from 1.97 to 12.17 over the past decade. While the company's 10-year median is 3.79 vs. the industry median of 2.79, Catalyst Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Catalyst Pharmaceuticals's current PB Ratio of 3.81 is 36.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Catalyst Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Catalyst Pharmaceuticals's current PB Ratio is 3.81, which is near median its own 10-year median of 3.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (FRA:CN2) is currently considered Significantly Overvalued. The stock's GF Value™ is €20.73, compared to a current price of €27.30 — trading 31.7% above its estimated fair value. The current PB Ratio is 3.81, which is near median its 10-year median of 3.79 and 36.6% above the Biotechnology industry median of 2.79. Catalyst Pharmaceuticals' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Catalyst Pharmaceuticals (FRA:CN2), the current PB Ratio is 3.81 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catalyst Pharmaceuticals (FRA:CN2) Overvalued in 2026?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued.
The current stock price of €27.30 is trading 31.7% above its estimated GF Value™ of €20.73.
GuruFocus considers Catalyst Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:CN2:
PB Ratio: 3.81 (near median its 10-year median of 3.79)
GF Value™: €20.73 vs. price of €27.30 (31.7% above fair value)
Industry Position: 36.6% above the Biotechnology median (#758 of 1229)
No single metric tells the full story. See the FRA:CN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
93GF Score
Get the complete analysis for FRA:CN2
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CN2 has been successfully added to your 
